熱門詞: 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
美國(guó)艾森生物科學(xué)公司(ACEA Biosciences Inc)
艾森生物科學(xué)公司(ACEA Biosciences Inc) 創(chuàng)建于2002年5月,公司位于美國(guó)加利福尼亞州的“生物硅谷”—-圣地亞哥,公司致力于開發(fā)具有國(guó)際先進(jìn)水平的生物細(xì)胞自動(dòng)分析系統(tǒng)等系列產(chǎn)品,以加速現(xiàn)代藥物開發(fā)和提高基礎(chǔ)生命科學(xué)研究水平,艾森已成功地研發(fā)出擁有自主知識(shí)產(chǎn)權(quán)、國(guó)際首創(chuàng)的微電子生物傳感器芯片及實(shí)時(shí)細(xì)胞分析系統(tǒng)等多項(xiàng)核心技術(shù),在無(wú)標(biāo)記生物檢測(cè)這個(gè)新穎的生物技術(shù)領(lǐng)域處于全球領(lǐng)先地位。
艾森生物(杭州)有限公司成立于2003年10月份,由艾森生物科學(xué)公司(ACEA Biosciences Inc.)獨(dú)資籌建,總部設(shè)在美國(guó)生物硅谷——加利福尼亞州的圣地亞哥市。
艾森生物(杭州)有限公司是一家集生產(chǎn)、研發(fā)、銷售、技術(shù)支持等為一體的高科技公司,致力于開發(fā)具有國(guó)際先進(jìn)水平的生物細(xì)胞自動(dòng)化分析系統(tǒng)等系列產(chǎn)品,其核心技術(shù)及產(chǎn)品——實(shí)時(shí)細(xì)胞分析系統(tǒng)獲得國(guó)家科技型中小企業(yè)技術(shù)創(chuàng)新獎(jiǎng)。公司目前已經(jīng)掌握了微電子生物細(xì)胞傳感器芯片制備、生物信號(hào)向電子信號(hào)轉(zhuǎn)化、數(shù)據(jù)采集和分析、配套分析軟件設(shè)計(jì)等國(guó)際先進(jìn)技術(shù),并擁有自主知識(shí)產(chǎn)權(quán),在國(guó)際生物芯片技術(shù)競(jìng)爭(zhēng)中處于領(lǐng)先的地位。
實(shí)時(shí)細(xì)胞分析系統(tǒng)具有實(shí)時(shí)監(jiān)控、高信息量、無(wú)需標(biāo)記、全自動(dòng)化、 高靈敏度和高準(zhǔn)確性等優(yōu)點(diǎn),極大地提高了藥物開發(fā)和基礎(chǔ)生命科學(xué)研究的自動(dòng)化過(guò)程及產(chǎn)出通量,并從根本上改進(jìn)人們從事細(xì)胞分子生物學(xué)研究的手段和方式。
公司用戶群包括全球500強(qiáng)的強(qiáng)生、輝瑞、默克等大型制藥公司,及世界頂級(jí)的研究機(jī)構(gòu),如美國(guó)衛(wèi)生研究院(NIH)、美國(guó)腫瘤研究所(NCI)、美國(guó)環(huán)境保護(hù)署(EPA)、哈佛大學(xué)、斯坦福大學(xué)、Scripps研究所、Salk研究所等。同時(shí),我們將積極進(jìn)行學(xué)術(shù)推廣,讓客戶充分了解該系統(tǒng)的優(yōu)越性,旨在優(yōu)化細(xì)胞生物研究的基礎(chǔ)技術(shù)平臺(tái)。
目前,艾森生物已經(jīng)與羅氏公司簽署了關(guān)于實(shí)時(shí)細(xì)胞技術(shù)的全球合作協(xié)議,協(xié)議規(guī)定由艾森生物負(fù)責(zé)對(duì)實(shí)時(shí)細(xì)胞檢測(cè)系統(tǒng)進(jìn)行新產(chǎn)品的開發(fā)及制造,由羅氏公司負(fù)責(zé)全球市場(chǎng)營(yíng)銷。2008年7月起協(xié)議正式生效。
ACEA Biosciences has pioneered the development of high-performance microelectronic systems for cell-based assays. Recently, ACEA Biosciences and Roche have entered into an exclusive agreement for the development, OEM supply and distribution for ACEA Bioscience’s real-time cell assay technology. ACEA and Roche are developing and marketing on a world-wide basis ACEA’s microplate-based biosensor platform for a variety of applications in drug development, toxicology, cancer research, and medical microbiology and virology. ACEA's products are designed to meet the increasing needs of the life science research and drug discovery markets by providing cost-effective, automated, high content, real time detection systems that simplify complex cell-based assay procedures and increase productivity.
The Roche-ACEA current product portfolio includes the RT-CA? microplate biosensor platform featuring 16 well and 96 well plates and individual workstations. In addition, a 6 X 96 multi-plate? station is now available to increase the assay throughput. Using the same microelectronic sensor technology, Roche and ACEA will soon launch the revolutionary real time migration analysis system. The system allows researchers to study the invasiveness of cancer cells in a highly quantitative, microplate- based, label-free, cost effective assay. With its international reach, ACEA Biosciences works closely with scientists throughout the world. Hangzhou, China is the site of ACEA's world-class manufacturing operations. Roche, as ACEA’s strategic partner, will assure the timely sales, service, and support of the Roche- ACEA growing product line throughout the world. ACEA Biosciences headquarters is in San Diego, California.